|
|
|
|
|
Brinzolamide
drug data and news
Brinzolamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Brinzolamide | ||
| Brand Names/Synonyms | Brinzolamide; Azopt; Brinzolamide [USAN]; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; Azopt | ||
| Indication | For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Used in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. | ||
| Mechanism Of Action | Brinxolamide is both a sulfonamide and a carbonic anhydrase II inhibitor. Carbonic anhydrase catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions, with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure, and thereby a reduction in the risk of optic nerve damage and glaucomatous visual field loss. | ||
| Brinzolamide News (When available) |
Brinzolamide 1% Found More Effective Than Brimonidine 0.15% When ... May 1, 2006 | ||
| Dosage Forms | SUSPENSION | ||
| Drug_Category | Antiglaucomic Agents; Ophthalmics; Carbonic Anhydrase Inhibitors; ATC:S01EC04 | ||
| Absorption | Not Available | ||
| Interactions | Interactions for Brinzolamide: AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor. Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-ethylamino-4-(3-methoxypropyl)-5,5-dioxo-5$l^{6},7-dithia-4-azabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide | ||
| Chemical Formula | C12H21N3O5S3 | ||
| Molecular Weight | 383.51 g/mol | ||
| Smiles String | CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | -0.222 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Ophthalmic | ||
| Half Life | 111 days | ||
| Protein Binding [%] | ~60% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Brinzolamide.html http://www.rxlist.com/cgi/generic3/brinzolamide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00475 | ||
| CAS Registry Number | 138890-62-7 | ||
| KEGG Compound ID | C07760 | ||
| PubChem ID | SID:210988 | ||
| PharmGKB ID | PA448667 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2238873 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |